Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Barron’s says this week’s 35% jump in Grail stock reflects a positive vote ahead of an FDA meeting with outside experts about approving the first blood test for many kinds of cancer; Grail is described as valued at $4.3 billion (19x the co…).
On Wednesday, GRAIL (NASDAQ: GRAL ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit The full earnings call is available at Summary GRAIL reported a strong second quarter 2026